Analysis and simulation are presented of the mismatched load condition for a balanced class-E power amplifier, which is based on 90° hybrids at its input and output. The performances of the 200-Watt balanced class-E amplifier, such as the output power and efficiency, were analyzed and compared to the conventional single-ended class-E power amplifier for the 1:3 VSWR mismatch condition. The simu...

This study aimed to describe (1) the prevalence of informational needs in surgically treated women with vulvar neoplasia during the first week after hospital discharge, (2) associations between informational needs and age, type, disease stage and the extent of surgery and (3) additional informational needs. This convergent parallel designed mixed-methods study was conducted in eight hospitals a...

modern audiences, again making it a bit more digestible at the level of undergraduates and general interest readers, although more seasoned Harvey scholars might also appreciate the added clarity, or where there is confusion, he has left the original Latin. For example, making reference to the 1928 translation by Chauncey Leake, Carty identifies confusion over the vena arteriosa and arteriae ve...

0

transmission of human pathogens can be occurred via inert objects. paper currency is a further common contact surface whereby pathogens can be transferred within a population although the significance remains unknown. hence, the aim of the present study was to investigate microbial populations associated with iranian paper currency.this study was carried out by getting 108 samples of the irania...

ETRI Journal, Volume 30, Number 1, February 2008 ABSTRACT⎯A highly linear and efficient GaN HEMT Doherty amplifier for wideband code division multiple access (WCDMA) repeaters is presented. For better performance, the adaptive gate bias control of the peaking amplifier using the power tracking circuit and the shunt capacitors is employed. The measured one-carrier WCDMA results show an adjacent ...

• Montelukast is an oral leukotriene receptor antagonist. It has had a UK licence since 1998 as addon therapy for the treatment of patients, 6 years or older, with mild to moderate asthma inadequately controlled on ‘as required’ short-acting β-agonists and inhaled corticosteroids. It is also licensed for prophylaxis of asthma in which the predominant component is exercise-induced bronchoconstri...